Results 21 to 30 of about 23,706 (182)

Dabigatran in Cerebral Sinus Vein Thrombosis and Thrombophilia

Life, 2022
Background and Purpose: Thrombophilic gene alterations are a major risk factor for cerebral sinus vein thrombosis (CSVT). Up to 30% of all patients with cerebral sinus vein thrombosis (CSVT) are found to have thrombophilic defects such as prothrombin ...
Lukas Kellermair, Matthias W. G. Zeller, Caterina Kulyk, Josef Tomasits, Tim J. von Oertzen, Milan R. Vosko   +5 more
doaj   +1 more source

Impact of Dabigatran Treatment on Rotation Thromboelastometry

Clinical and Applied Thrombosis/Hemostasis, 2021
A rapid and reliable assessment of the dabigatran effect is desirable in dabigatran treated patients with uncontrolled bleeding or before acute surgery.
Juraj Sokol MD, PhD, Frantisek Nehaj MD, Jela Ivankova RNDr, Michal Mokan MD, PhD, Jana Zolkova RNDr, Lenka Lisa MD, PhD, Ludmila Linekova MD, Marian Mokan MD, DSc, FRCP Edin, Jan Stasko MD, PhD   +8 more
doaj   +1 more source

The preoperative management of dabigatran and its specific antidote idarucizumab in patients with nonvalvular atrial fibrillation: Case reports [PDF]

Arhiv za farmaciju, 2020
Dabigatran is a novel oral anticoagulant preferred due to its ease of use, favorable pharmacokinetics, decreased potential for drug-drug interactions, and the lack of monitoring requirements.
Tomić Milan
doaj   +1 more source

Inside the ‘Black Box’ of Pharmaceuticalisation: NICE, the Permissive Principle and the Case of Anticoagulants [PDF]

Sociol Health Illn
ABSTRACT Sociological interest in pharmaceuticalisation continues to grow, especially regarding the expansion of pharmaceutical use in society. This article presents the first major empirical study focusing on the directionality of pharmaceuticalisation by taking cost‐effectiveness assessment and regulation of anticoagulants in England by the National ...
Abraham J, Balendran G.
europepmc   +2 more sources

Measurement of Dabigatran Concentration Using Finger Prick Dried Blood Spot Sample Collection

Frontiers in Pharmacology, 2021
Background and Purpose: Real-world laboratory monitoring of dabigatran activity is challenging. The purpose of the present study was to demonstrate the feasibility and accuracy of finger prick sampling with dried blood spot (fpDBS) cards in measuring the
Shin-Yi Lin, Shin-Yi Lin, Yu-Fong Peng, Chih-Fen Huang, Chih-Fen Huang, Ching-Hua Kuo, Sung-Chun Tang, Jiann-Shing Jeng   +7 more
doaj   +1 more source

Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases [PDF]

, 2013
We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion who received rt-PA for thrombolysis while on oral anticoagulant treatment with dabigatran (150 mg b.i.d.).
Baas, Horst, Mario Abruscato, Susanne Hövelmann, Pfeilschifter, Waltraud, Abruscato, Mario Giovanni Rosario, Hövelmann, Susanne, Horst Baas, Waltraud Pfeilschifter   +7 more
core   +1 more source

Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation

Journal of Arrhythmia, 2015
Background: Activated partial thromboplastin time (aPTT) is recommended for monitoring anticoagulant activity in dabigatran-treated patients; however, there are limited data in Japanese patients.
Daiki Shimomura, Yoshihisa Nakagawa, MD, Hirokazu Kondo, MD, Toshihiro Tamura, MD, Masashi Amano, MD, Yukiko Hayama, MD, Naoaki Onishi, MD, Yodo Tamaki, MD, Makoto Miyake, MD, Kazuaki Kaitani, MD, Chisato Izumi, MD, Masahiko Hayashida, Aya Fukuda, Fumihiko Nakamura, MD, Seiji Kawano, MD   +14 more
doaj   +1 more source

No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke [PDF]

, 2012
Background: Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-to-benefit profile of DE compared to warfarin. In this study, we evaluated whether hemorrhagic transformation (HT) occurs after
Ferdinand Bohmann, Christian Foerch (149410), Edelgard Lindhoff-Last (149408), Ferdinand Bohmann (149406), Mirceska, Ana, Ana Mirceska, Förch, Christian, Waltraud Pfeilschifter, Pfeilschifter, Josef (Prof. Dr.), Bohmann, Ferdinand, Edelgard Lindhoff-Last, Waltraud Pfeilschifter (149411), Helmuth Steinmetz, Steinmetz, Helmuth, Christian Foerch, Helmuth Steinmetz (149409), Pfeilschifter, Waltraud, Josef Pfeilschifter, Josef Pfeilschifter (92946), Ana Mirceska (149407), Lindhoff-Last, Edelgard, Bohmann Ferdinand, Steinmetz Helmuth, Mirceska Ana, Lindhoff-Last Edelgard, Pfeilschifter Waltraud, Foerch Christian, Pfeilschifter Josef   +27 more
core   +2 more sources

A national audit on the utilization and documentation of dabigatran checklist for patients initiated on dabigatran [PDF]

, 2019
Background: Direct oral anticoagulants (DOACs) especially dabigatran, have gain popularity for their efficacy, fixed dosing and favourable safety profile.
Mohamad, Noraini, George, Doris, Devaraj, Navin Kumar, Rahmat, Shakirin Shaik, Mohamed, Sahimi   +4 more
core   +2 more sources

Effect of Dabigatran on Clotting Time in the Clotpro Ecarin Clotting Assay: A Prospective, Single-Arm, Open-Label Study

Clinical and Applied Thrombosis/Hemostasis, 2020
Routine coagulation tests do not enable rapid, accurate determination of direct oral anticoagulant (DOAC) therapy. The ecarin clotting assay (ECA), performed on the ClotPro viscoelastic testing device, may enable sensitive and specific detection of ...
Alan Yean Yip Fong MRCP, Lee Len Tiong BPharm, Shirley Siang Ning Tan BPharm, Dominic Geruka BSc, Gerald Grino Apil BSc, Chee Wei Choo MSc, Tiong Kiam Ong MRCP   +6 more
doaj   +1 more source